DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd.
DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed a lawsuit against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd. for patent infringement.
SINGAPORE, Oct. 09, 2017 (GLOBE NEWSWIRE) — DSM Sinochem Pharmaceuticals announced today that its wholly owned subsidiary, DSM Sinochem Pharmaceuticals Netherlands B.V. filed a lawsuit against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd. (“CSPC”) for patent infringement in the District Court of The Hague, Afdeling Handel (commercial division), Netherlands, for patent infringement of the Dutch part of European Patent Number 1,610,766 B1. This patent, which is owned by DSP, describes and claims amoxicillin trihydrate having a low free water content and processes for the manufacture thereof. By its complaint, DSP seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use, importation and sale of CSPC’s amoxicillin active pharmaceutical ingredient, and/or any drug product that utilizes the active pharmaceutical, in the Netherlands.
“DSP has a world class intellectual property (IP) portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology,” said Karl Rotthier, CEO at DSP. “After having previously filed patent litigation against Sinopharm Weiqida Pharmaceutical for patent infringement in India and the Netherlands in January 2017, DSP will continue to rigorously enforce its IP assets worldwide against any additional potential infringers as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”
DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
This press release may contain forward-looking statements with respect to DSM Sinochem Pharmaceuticals’ (DSP) future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSP and information currently available to the company. DSP cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSP has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Please visit www.dsm-sinochem.com for more information or contact
DSM Sinochem Pharmaceuticals Corporate Communications
Alice Beijersbergen, Global Director Branding & Communications
DSM Sinochem Pharmaceuticals Corporate Communications www.dsm-sinochem.com